Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.
Cancer is sporadic in nature, characterized by an initial clonal oncogenic event and usually a long latency. When and how it subverts the immune system is unknown. We show, in a model of sporadic immunogenic cancer, that tumor-specific tolerance closely coincides with the first tumor antigen recognition by B cells. During the subsequent latency period until tumors progress, the mice acquire general cytotoxic T lymphocyte (CTL) unresponsiveness, which is associated with high transforming growth factor (TGF) beta1 levels and expansion of immature myeloid cells (iMCs). In mice with large nonimmunogenic tumors, iMCs expand but TGF-beta1 serum levels are normal, and unrelated CTL responses are undiminished. We conclude that (a) tolerance to the tumor antigen occurs at the premalignant stage, (b) tumor latency is unlikely caused by CTL control, and (c) a persistent immunogenic tumor antigen causes general CTL unresponsiveness but tumor burden and iMCs per se do not.
Institute of Immunology, Charité Campus Benjamin Franklin, 12200 Berlin, Germany.
Gerald
G
Willimsky
Melinda
M
Czéh
Christoph
C
Loddenkemper
Johanna
J
Gellermann
Karin
K
Schmidt
Peter
P
Wust
Harald
H
Stein
Thomas
T
Blankenstein
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D007108:Immune Tolerance; D051379:Mice; D018345:Mice, Knockout; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000473:pathology; D053773:Transforming Growth Factor beta1 / Q000276:immunology
D000951:Antigens, Neoplasm; D053773:Transforming Growth Factor beta1